Skip to content

InvestNot yet confirmed elsewhere1 publisher3 min readPublished

North Gyeongsang adds a 175 billion won hemp drug chain in Andong to its 1.5 trillion won foundry plan

North Gyeongsang plans a 175 billion won hemp-to-medicine supply chain in Andong by 2030 as part of a 1.5 trillion won plan for four foundries. Pooling provincial capital, private funds and policy financing is meant to cut what companies spend before production starts.

The Investor · Invest desk

How we use AISend a correction

Illustration accompanying North Gyeongsang adds a 175 billion won hemp drug chain in Andong to its 1.5 trillion won foundry plan
Generated illustration
Gumi holds about 76% of North Gyeongsang's foundry plan Planned investment by site in North Gyeongsang's foundry plan; the Gumi figure is what remains of the plan after Andong and Pohang.

Bar comparison of planned investment: Andong hemp drug chain 175 billion won, Pohang robot foundry about 180 billion won, and Gumi's quantum and chip foundries about 1.15 trillion won, roughly 76% of the plan.

Gumi holds about 76% of North Gyeongsang's foundry plan (Planned investment by site within the provincial foundry plan)
ItemValueClaim
Andong hemp drug chain175 billion won4
Pohang robot foundry180 billion won9
Gumi quantum and chip foundries1,150 billion won15

What happened

  • On the 12th, the province is due to sign an agreement with Andong city, Neoken Bio and the Korea Regional Revitalization Investment and Development Institute.
  • Robotics firm Neuromeka agreed last month to build a robot foundry worth about 180 billion won in Pohang, funded through a regional revitalization investment fund.
  • Last month in the United States, the province and Gumi city signed an agreement for a quantum-industry foundry with IonQ and its partner SDT.
  • A separate Gumi foundry for automotive system and power chips is expected to draw the largest investment of the four.

Why it matters

  • exposure Companies that rent foundry lines skip building their own plants, so the co-investors that own the lines take the loss if contract orders fall short.
  • constraint With about 76% of the 1.5 trillion won left for Gumi, demand for chip and quantum capacity decides most of the plan's outcome, whatever happens to hemp in Andong.
  • decision Putting about 78% of Pohang's figure into a second phase leaves Neuromeka and its fund room to stop at 40 billion won if the first lines go unfilled.

Two of the four foundries now have figures attached, and together they account for under a quarter of the money. Andong's 175 billion won [4] and Pohang's roughly 180 billion won [9] add to 355 billion won, about 24% of the 1.5 trillion won plan [1][14]. Andong has the smallest disclosed figure, or rather, since Pohang's number is approximate, it is roughly tied with Pohang [4][9]. That leaves about 1.15 trillion won, some 76% of the total, for Gumi, where the province is pursuing both a quantum foundry and a chip foundry [15][7][11]. The chip plant is the expected largest of the four [12]. If the 1.5 trillion won is the sum of the four budgets, that plant needs at least about 570 billion won, more than Andong and Pohang combined [16].

Pohang's money comes in two pieces. The first phase is 40 billion won for lines that make and contract-manufacture collaborative and humanoid robots, with groundbreaking targeted for next month. A 140 billion won second phase follows [10]. The first tranche is about 22% of the project [17].

The pooled structure is meant to lower companies' initial investment burden and risk [2]. Whether it does depends on who takes the first loss inside the pool. The province did not disclose how any foundry's funding divides among its own capital, private funds and policy financing. Should provincial money and policy lenders sit beneath the private funds, tenants get cheaper entry and the public side owns the risk of empty lines. If private funds and anchor companies put up most of the capital instead, the co-investment structure changes little about who pays when a line runs below capacity. A third outcome sits outside the funding split: Gumi's chip plant fills while the smaller bio and robot sites run under capacity, and the totals hide the weak sites. We think the structure does lower entry costs for companies that rent capacity. A funding split in which companies still supply most of the money would prove that wrong.

The vice governor's own description keeps companies in the fundraising. Yang Kum-hee, vice governor for economic affairs, said the province will "push ahead quickly with the four foundries through a co-investment approach in which local government joins companies in raising funds and connects them to policy financing." [13]

Andong's project starts at the farm. It covers hemp growing, the manufacture of active pharmaceutical ingredients and finished drugs, and quality and safety management [4]. Cultivation sites and drug plants would be linked into one local production system [6]. The hemp is cannabis with less than 0.3% THC, the psychoactive compound, and is the source of cannabidiol, a compound used in treating conditions such as epilepsy [5].

What to watch

  • A published investment figure for the Gumi automotive and power chip foundry, and the names of companies that will rent its lines.
  • Whether companies other than Neuromeka sign contract-manufacturing orders for the Pohang collaborative and humanoid robot lines.

Clarity's read

What the record supports and how the coverage leans. The claims behind it follow.

Reality

Evidence40
Adoption15
Hype gap+30
Incentives60
Confidence40
Why these scores

Claim ledger

Ranked by verification strength, evidence, and original report placement.

  1. [1]

    North Gyeongsang Province is fleshing out a 1.5 trillion won plan to build four manufacturing foundries for advanced industries, expanding from robotics and quantum technology into biotechnology.

    ReportedSupportedView cited source
  2. [2]

    The plan uses a co-investment structure combining provincial government capital, private funds and policy financing to reduce companies' initial investment burden and risk.

    ReportedSupportedView cited source
  3. [3]

    The province said on the 11th it will sign a memorandum of understanding on the 12th with the city of Andong, Neoken Bio and the Korea Regional Revitalization Investment and Development Institute to build a specialty pharmaceutical value chain in Andong.

    ReportedSupportedView cited source

Sources

1 independent publisher whose own reporting we read for this story.

  1. en.sedaily.com

    1 article · October 11, 2026

    North Gyeongsang Builds 1.5 Trillion Won Advanced Manufacturing Base

Share your take

Let Clarity write the post for you.

Signed-in readers get a short post drafted on this story in the register they choose — narrative, analytical, or a direct position — editable to the last word before it goes anywhere. The share buttons at the top of this story work without an account.

Topics and entities

Follow any of these and your For You feed starts watching them — no settings page required.

Topics

  • Contract manufacturingFollow
  • Quantum technologyFollow
  • Hemp-derived pharmaceuticalsFollow
  • South Korean regional industrial policyFollow

Entities

Loading related stories